Patents by Inventor Akito Shibuya

Akito Shibuya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE
    Publication number: 20240066047
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: May 1, 2023
    Publication date: February 29, 2024
    Inventors: MASATO YOSHIKAWA, MORIHISA SAITOH, TAISUKE KATO, YAYOI NAKAYAMA, TOMOHIRO SEKI, YASUO NAKAGAWA, YUSUKE TOMINARI, MASAKI SETO, YUSUKE SASAKI, MASANORI OKANIWA, TSUNEO ODA, AKITO SHIBUYA, KOSUKE HIDAKA, ZENYU SHIOKAWA, SHUMPEI MURATA, ATSUTOSHI OKABE, YOSHIHISA NAKADA, MICHIYO MOCHIZUKI, BRIAN SCOTT FREEZE, TAISUKE TAWARAISHI, YASUFUMI WADA, PAUL D. GREENSPAN
  • Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors
    Patent number: 11795172
    Abstract: The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: October 24, 2023
    Assignee: Cardurion Pharmaceuticals, Inc.
    Inventors: Nobuyuki Matsunaga, Junya Shirai, Tomohiro Okawa, Yasufumi Miyamoto, Zenyu Shiokawa, Takashi Nakahata, Akito Shibuya, Akira Kawada, Malcolm MacCoss
  • Antibody-drug conjugates comprising a cyclic dinucleotide
    Patent number: 11666594
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: June 6, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masato Yoshikawa, Morihisa Saitoh, Taisuke Kato, Yayoi Nakayama, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Yusuke Sasaki, Masanori Okaniwa, Tsuneo Oda, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Shumpei Murata, Atsutoshi Okabe, Yoshihisa Nakada, Michiyo Mochizuki, Brian Scott Freeze, Taisuke Tawaraishi, Yasufumi Wada, Paul D. Greenspan
  • AMINOPYRIMIDINE COMPOUND
    Publication number: 20220112184
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: September 24, 2021
    Publication date: April 14, 2022
    Inventors: Nobuyuki MATSUNAGA, Yasufumi MIYAMOTO, Junya SHIRAI, Takashi NAKAHATA, Zenyu SHIOKAWA, Tomohiro OKAWA, Akito SHIBUYA, Malcolm MACCOSS
  • FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS
    Publication number: 20220098207
    Abstract: The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 24, 2021
    Publication date: March 31, 2022
    Inventors: Nobuyuki MATSUNAGA, Junya SHIRAI, Tomohiro OKAWA, Yasufumi MIYAMOTO, Zenyu SHIOKAWA, Takashi NAKAHATA, Akito SHIBUYA, Akira KAWADA, Malcolm MACCOSS
  • Substituted amines for treating cardiac diseases
    Patent number: 11197858
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: December 14, 2021
    Assignee: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki Matsunaga, Takashi Nakahata, Yuta Tanaka, Hiroki Takahagi, Yasufumi Miyamoto, Rei Okamoto, Takeshi Yoshikawa, Yoshito Terao, Takafumi Yukawa, Keiko Kakegawa, Yoichi Nishikawa, Terufumi Takagi, Masashi Takahashi, Mallareddy Komandla, Lily Kwok, Joanne Miura, Mark Sabat, Nicholas Scorah, Paul Tanis, John Tyhonas, Phong H. Vu, Haixia Wang, Xiaolun Wang, Junya Shirai, Tomohiro Okawa, Zenyu Shiokawa, Akito Shibuya
  • Aromatic compound
    Patent number: 11186565
    Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: November 30, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Seiji Miwatashi, Yasufumi Miyamoto, Koji Watanabe, Yayoi Nakayama, Yuko Hitomi, Jumpei Aida, Nobuyuki Takakura, Hideki Furukawa, Naoyoshi Noguchi, Yasuhiro Hirata, Kazuaki Takami, Norihito Tokunaga, Tomohiro Okawa, Akito Shibuya, Shizuo Kasai, Toshitake Kobayashi, Tsuyoshi Maekawa
  • Aminopyrimidine compound
    Patent number: 11130752
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: September 28, 2021
    Assignee: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki Matsunaga, Yasufumi Miyamoto, Junya Shirai, Takashi Nakahata, Zenyu Shiokawa, Tomohiro Okawa, Akito Shibuya, Malcolm MacCoss
  • CYCLIC DINUCLEOTIDE
    Publication number: 20210137962
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 13, 2021
    Inventors: Masato Yoshikawa, Morihisa Saitoh, Taisuke Kato, Yayoi Yoshitomi, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Yoshihisa Nakada, Michiyo Mochizuki
  • Cyclic dinucleotide
    Patent number: 10980825
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: April 20, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masato Yoshikawa, Morihisa Saitoh, Taisuke Kato, Yayoi Nakayama, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Yoshihisa Nakada, Michiyo Mochizuki
  • ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE
    Publication number: 20210106607
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: October 7, 2020
    Publication date: April 15, 2021
    Inventors: MASATO YOSHIKAWA, Morihisa Saitoh, Taisuke Kato, Yayoi Nakayama, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Yusuke Sasaki, Masanori Okaniwa, Tsuneo Oda, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Shumpei Murata, Atsutoshi Okabe, Yoshihisa Nakada, Michiyo Mochizuki, Brian Scott Freeze, Taisuke Tawaraishi, Yasufumi Wada, Paul D. Greenspan
  • SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES
    Publication number: 20200230137
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: January 27, 2020
    Publication date: July 23, 2020
    Applicant: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki MATSUNAGA, Takashi NAKAHATA, Yuta TANAKA, Hiroki TAKAHAGI, Yasufumi MIYAMOTO, Rei OKAMOTO, Takeshi YOSHIKAWA, Yoshito TERAO, Takafumi YUKAWA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Terufumi TAKAGI, Masashi TAKAHASHI, Mallareddy KOMANDLA, Lily KWOK, Joanne MIURA, Mark SABAT, Nicholas SCORAH, Paul TANIS, John TYHONAS, Phong H. VU, Haixia WANG, Xiaolun WANG, Junya SHIRAI, Tomohiro OKAWA, Zenyu SHIOKAWA, Akito SHIBUYA
  • AMINOPYRIMIDINE COMPOUND
    Publication number: 20200095240
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: September 24, 2019
    Publication date: March 26, 2020
    Inventors: Nobuyuki MATSUNAGA, Yasufumi MIYAMOTO, Junya SHIRAI, Takashi NAKAHATA, Zenyu SHIOKAWA, Tomohiro OKAWA, Akito SHIBUYA, Malcolm MacCoss
  • Substituted amines for treating cardiac diseases
    Patent number: 10543212
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: January 28, 2020
    Assignee: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki Matsunaga, Takashi Nakahata, Yuta Tanaka, Hiroki Takahagi, Yasufumi Miyamoto, Rei Okamoto, Takeshi Yoshikawa, Yoshito Terao, Takafumi Yukawa, Keiko Kakegawa, Yoichi Nishikawa, Terufumi Takagi, Masashi Takahashi, Mallareddy Komandla, Lily Kwok, Joanne Miura, Mark Sabat, Nicholas Scorah, Paul Tanis, John Tyhonas, Phong H. Vu, Haixia Wang, Xiaolun Wang, Junya Shirai, Tomohiro Okawa, Zenyu Shiokawa, Akito Shibuya
  • CYCLIC DINUCLEOTIDE
    Publication number: 20190192549
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: June 27, 2019
    Inventors: MASATO YOSHIKAWA, Morihisa Saitoh, Taisuke Kato, Yayoi Yoshitomi, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Yusuke Sasaki, Masanori Okaniwa, Tsuneo Oda, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Shumpei Murata, Atsutoshi Okabe, Yoshihisa Nakada, Michiyo Mochizuki, Brian Scott Freeze, Taisuke Tawaraishi, Yasufumi Wada, Paul D. Greenspan
  • HETEROCYCLIC COMPOUND
    Publication number: 20180280389
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: March 23, 2018
    Publication date: October 4, 2018
    Applicant: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki MATSUNAGA, Takashi NAKAHATA, Yuta TANAKA, Hiroki TAKAHAGI, Yasufumi MIYAMOTO, Rei OKAMOTO, Takeshi YOSHIKAWA, Yoshito TERAO, Takafumi YUKAWA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Terufumi TAKAGI, Masashi TAKAHASHI, Mallareddy KOMANDLA, Lily KWOK, Joanne MIURA, Mark SABAT, Nicholas SCORAH, Paul TANIS, John TYHONAS, Phong H. VU, Haixia WANG, Xiaolun WANG, Junya SHIRAI, Tomohiro OKAWA, Zenyu SHIOKAWA, Akito SHIBUYA
  • Heterocyclic compound
    Patent number: 9890145
    Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: February 13, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masato Yoshida, Kazuaki Takami, Yusuke Tominari, Zenyu Shiokawa, Akito Shibuya, Yusuke Sasaki, Tony Gibson, Terufumi Takagi
  • Aromatic compounds with GPR40 agonistic activity
    Patent number: 9776962
    Abstract: Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: October 3, 2017
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jumpei Aida, Yayoi Yoshitomi, Yuko Hitomi, Naoyoshi Noguchi, Yasuhiro Hirata, Hideki Furukawa, Akito Shibuya, Koji Watanabe, Yasufumi Miyamoto, Tomohiro Okawa, Nobuyuki Takakura, Seiji Miwatashi
  • HETEROCYCLIC COMPOUND
    Publication number: 20160311811
    Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: April 25, 2016
    Publication date: October 27, 2016
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masato YOSHIDA, Kazuaki TAKAMI, Yusuke TOMINARI, Zenyu SHIOKAWA, Akito SHIBUYA, Yusuke SASAKI, Tony GIBSON, Terufumi TAKAGI
  • Aromatic ring compound
    Patent number: 9382188
    Abstract: Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: July 5, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Seiji Miwatashi, Hideo Suzuki, Tomohiro Okawa, Yasufumi Miyamoto, Takeshi Yamasaki, Yuko Hitomi, Yasuhiro Hirata, Akito Shibuya